Akp and Ggt Level Can Provide An Early Prediction of First-Line Treatment Efficacy in Colorectal Cancer Patients with Hepatic Metastases

Reference

• Zarour LR , AnandS, BillingsleyKGet al. Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell Mol. Gastroenterol. Hepatol.3(2), 163–173 (2017).
   PubMed Web of Science ®Google Scholar
• Mo S , CaiX, ZhouZet al. Nomograms for predicting specific distant metastatic sites and overall survival of colorectal cancer patients: a large population-based real-world study. Clin. Transl. Med.10(1), 169–181 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang J , YanS, LiuXet al. Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. Carcinogenesis38(8), 837–846 (2017).
   PubMed Web of Science ®Google Scholar
• Mo S , ZhouZ, DaiWet al. Development and external validation of a predictive scoring system associated with metastasis of T1-2 colorectal tumors to lymph nodes. Clin. Transl. Med.10(1), 275–287 (2020).
   PubMed Web of Science ®Google Scholar
• Jiang X , LiuG, HuZ, ChenG, ChenJ, LvZ. cGAMP inhibits tumor growth in colorectal cancer metastasis through the STING/STAT3 axis in a zebrafish xenograft model. Fish Shellfish Immunol.95, 220–226 (2019).
   PubMed Web of Science ®Google Scholar
• Tomlinson JS , JarnaginWR, DematteoRPet al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol.25(29), 4575–4580 (2007).
   PubMed Web of Science ®Google Scholar
• Pawlik TM , ScogginsCR, ZorziDet al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg.241(5), 715–722 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen SJ , PuntCJ, IannottiNet al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol.26(19), 3213–3221 (2008).
   PubMed Web of Science ®Google Scholar
• Matsusaka S , SuenagaM, MishimaYet al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci.102(6), 1188–1192 (2011).
   PubMed Web of Science ®Google Scholar
• Tartter PI , SlaterG, GelerntI, AufsesAHJr. Screening for liver metastases from colorectal cancer with carcinoembryonic antigen and alkaline phosphatase. Ann. Surg.193(3), 357–360 (1981).
   PubMed Web of Science ®Google Scholar
• Heinrich D , BrulandO, GuiseTA, SuzukiH, SartorO. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol.14(24), 2543–2556 (2018).
   PubMed Web of Science ®Google Scholar
• Kellen JA , BushRS, MalkinA. Placenta-like alkaline phosphatase in gynecological cancers. Cancer Res.36(1), 269–271 (1976).
   PubMed Web of Science ®Google Scholar
• Qin S , LiJ, WangLet al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, Phase III TAILOR trial. J. Clin. Oncol.36(30), 3031–3039 (2018).
   PubMed Web of Science ®Google Scholar
• Aronsen KF , HansonA, NosslinB. The value of γ-glutamyl transpeptidase in differentiating viral hepatitis from obstructive jaundice. A statistical comparison with alkaline phosphatase. Acta Chir. Scand.130, 92–99 (1965).
   PubMedGoogle Scholar
• Aronsen KF , NosslinB, PihlB. The value of glutamyl transpeptidase in detection of liver metastases in patients with abdominal cancer. Scand. J. Clin. Lab. Invest. Suppl.100, 107 (1967).
   PubMedGoogle Scholar
• Prager GW , BraemswigKH, MartelAet al. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci.105(8), 996–1001 (2014).
   PubMed Web of Science ®Google Scholar
• Jia J , ZhangP, GouM, YangF, QianN, DaiG. The role of serum CEA and CA19-9 in efficacy evaluations and progression-free survival predictions for patients treated with cetuximab combined with FOLFOX4 or FOLFIRI as a first-line treatment for advanced colorectal cancer. Dis. Markers2019, 6812045 (2019).
   PubMed Web of Science ®Google Scholar
• Nakamura Y , YoshinoT. Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer. Oncologist23(11), 1310–1318 (2018).
   PubMed Web of Science ®Google Scholar
• Tie J , KindeI, WangYet al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol.26(8), 1715–1722 (2015).
   PubMed Web of Science ®Google Scholar
• Vymetalkova V , CervenaK, BartuL, VodickaP. Circulating cell-free DNA and colorectal cancer: a systematic review. Int. J. Mol. Sci.19(11), 3356 (2018).
   PubMed Web of Science ®Google Scholar
• Goldberg SB , NarayanA, KoleAJet al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin. Cancer Res.24(8), 1872–1880 (2018).
   PubMed Web of Science ®Google Scholar
• Ah-See ML , MakrisA, TaylorNJet al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res.14(20), 6580–6589 (2008).
   PubMed Web of Science ®Google Scholar
• Wang C , GuoW, ZhouMet al. The predictive and prognostic value of early metabolic response assessed by positron emission tomography in advanced gastric cancer treated with chemotherapy. Clin. Cancer Res.22(7), 1603–1610 (2016).
   PubMed Web of Science ®Google Scholar
• Kaira K , HiguchiT, NaruseIet al. Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur. J. Nucl. Med. Mol. Imaging45(1), 56–66 (2018).
   PubMed Web of Science ®Google Scholar